With the greater use of low-dose CT along with the adoption of lung cancer screening programs across the United States, the incidental detection of lung nodules is expected to increase. 1 , 2 Although most incidentally detected nodules are benign
Search Results
Bronchoscopic Techniques Used in the Diagnosis and Staging of Lung Cancer
Andrew D. Lerner and David Feller-Kopman
Compound Kushen Injection Reduces Severe Toxicity and Symptom Burden Associated With Curative Radiotherapy in Patients With Lung Cancer
Jie Liu, Qingxi Yu, Xin Shelley Wang, Qiuling Shi, Jun Wang, Fan Wang, Simeng Ren, Jiayue Jin, Baojin Han, Wenzheng Zhang, Xueyao Su, Shuanghu Yuan, and Hongsheng Lin
Background Approximately half of patients with locally advanced lung cancer will receive radiotherapy (RT). 1 However, thoracic RT induces adverse events (AEs) involving the main chest organs, such as the lungs, heart, and esophagus
Stereotactic Ablative Radiotherapy for Non–Small Cell Lung Cancer: Rationale and Outcomes
Puneeth Iyengar and Robert D. Timmerman
The concept of stereotactic ablative radiotherapy (SABR), known in older reports as stereotactic body radiation therapy (SBRT), for the treatment of lung cancer traces its roots back to the use of stereotactic radiosurgery in the treatment of
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Apar Kishor P. Ganti, Billy W. Loo Jr., Michael Bassetti, Collin Blakely, Anne Chiang, Thomas A. D'Amico, Christopher D'Avella, Afshin Dowlati, Robert J. Downey, Martin Edelman, Charles Florsheim, Kathryn A. Gold, Jonathan W. Goldman, John C. Grecula, Christine Hann, Wade Iams, Puneeth Iyengar, Karen Kelly, Maya Khalil, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar Moran, Saraswati Pokharel, Sonam Puri, Angel Qin, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Michael Shafique, Saiama N. Waqar, Kristina M. Gregory, and Miranda Hughes
Overview Neuroendocrine tumors account for approximately 20% of lung cancers; most (approximately 14%) are small cell lung cancer (SCLC). 1 , 2 In 2021, an estimated 33,000 new cases of SCLC will occur in the United States. 1 , 3 During the
Non-Small Cell Lung Cancer Guidelines
Lung cancer is still the leading cause of cancer death worldwide, and non-small cell lung cancer accounts for 80% to 85% of all lung cancer cases. Surgery, radiation therapy, and chemotherapy are the 3 modalities commonly used to treat patients with NSCLC and can be used either alone or in combination depending on the disease status. The 2006 NCCN Non-Small Cell Lung Cancer Guidelines provide the latest updates in the management of this disease, including stage regrouping and changes in screening recommendations for high-risk patients and in treatment recommendations for several stages. In addition, principles of systemic therapy were expanded to include adjuvant treatment.
For the most recent version of the guidelines, please visit NCCN.org
Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology
Lung cancer is the leading cause of cancer death in both men and women in the United States. An estimated 171,900 new cases (91,800 in men, 80,100 in women) of lung cancer will be diagnosed in 2003, and 157,200 deaths (88,400 in men, 68,800 in women) will occur due to the disease. Only 14% of all lung cancer patients will be alive 5 years or more after diagnosis. The primary risk factor for lung cancer is smoking, which accounts for over 85% of all lung cancer-related deaths. The guidelines discuss diagnosis, staging, therapy, and surveillance for non-small cell lung cancer.
For the most recent version of the guidelines, please visit NCCN.org
CLO19-030: Duration of First Line Therapy in Metastatic Non-Small Cell Lung Cancer
Jeff Dang, Sang Chau, Jessy Delaisla, Divya Prakash, and Andrew Hertler
Background: Lung cancer is the leading cause of death in the United States. We are challenged with finding the optimal treatment for patient subgroups in a real-world setting. Treatment options have expanded to include immunotherapies versus
Role of Prophylactic Cranial Irradiation in Extensive-Stage Small Cell Lung Cancer
Nathan Y. Yu, Terence T. Sio, Vinicius Ernani, Panayiotis Savvides, and Steven E. Schild
therapy in limited small-cell lung cancer . Cancer Clin Trials 1981 ; 4 : 261 – 266 . 6269769 4. Lukas RV , Gondi V , Kamson DO , State-of-the-art considerations in small cell lung cancer brain metastases . Oncotarget 2017 ; 8
Small Cell Lung Cancer Guidelines
In 2005, approximately 26,000 new cases of small cell lung cancer were diagnosed in the United States. When compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy. Treatment with chemotherapy plus chest radiotherapy can be curative for some patients with limited-stage SCLC, whereas most patients with extensive-stage disease who undergo chemotherapy alone experience palliated symptoms and prolonged survival. The updated 2006 NCCN guidelines include new principles of surgical resection as well as chemotherapy and radiation dosage changes.
For the most recent version of the guidelines, please visit NCCN.org
EGFR-Mutant Non–Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing
Ammar Sukari, Misako Nagasaka, and Erin Wakeling
Precision medicine has rapidly been applied by oncologists who treat non–small cell lung cancer (NSCLC). In patients with newly diagnosed advanced-stage NSCLC, it is now considered standard of care to offer treatment regimens based on molecular
